The exact schedule depends on the product label, the indication, prior exposure, missed doses, and clinician judgment
*Semaglutide is not an option if you have a history of medullary thyroid cancer, gallbladder disease, pancreatitis, or MEN2 While contraindications are few and far between, certain health issues, pregnancy, or breastfeeding may rule out some candidates
February 4, 2026- Elli Lilly will be awarded regulatory approval, in 2nd quarter of 2026, for the pill version of its GLP-1 drugs
Semaglutide is so successful for weight management because it provides a number of benefits that make losing weight much easier
Your provider will assess your medical profile, including current medications and lifestyle, to ensure the suitability of Semaglutide for you